What a prescription can and cannot settle
TB-500 isn't approved, and pharmacy permission remains unclear
Does a prescription let your pharmacy provide TB-500? The ingredient needs separate permission. FDA hasn't explained permission following withdrawal of the request.
A withdrawn request leaves the safety warning in place
Does TB-500 have drug approval for your treatment? No, FDA hasn't approved TB-500 as a drug. FDA is the U.S. agency overseeing drug safety. The agency names the substance as part of thymosin beta-4.
The original Category 2 listing flagged possible serious harm.
FDA's list was updated September 29, 2023. The agency warned of missing safety knowledge and possible immune reactions [16]. Your body's defenses might attack the substance instead of accepting it.
The later entry didn't remove the safety concerns.
A request sought permission for TB-500 as a pharmacy ingredient. That request was later withdrawn, meaning taken back. FDA still shows you the safety warning beside the withdrawn request [16][17].
Taking a request back isn't receiving permission.
FDA hasn't said how pharmacies may proceed after withdrawal. These pharmacies prepare medicine for you as an individual patient. Their ingredient rules are separate from rules for approving finished drugs.
No finished TB-500 drug has approval for your care [16].
A pharmacy-made medicine doesn't automatically have drug approval either. The unresolved TB-500 ingredient question still matters for your prescription. You need an ingredient the pharmacy is allowed to use.
FDA's entry concerns TB-500 rather than the whole protein [16].
Results from thymosin beta-4 can't settle the shorter substance's safety. Your prescription doesn't supply that missing evidence.
The July adviser meeting didn't settle pharmacy access
What happened at the July 2026 adviser meeting? FDA sought advice about allowing TB-500 in pharmacy-made medicines. The advisers met July 23-24, 2026 [18].
Discussion wasn't permission for your pharmacy.
The agenda named TB-500 with and without added salt. The salt-free form is called free base. The salt-added form is called acetate. Neither form gained approval just by appearing on that agenda.
The agenda also named BPC-157, KPV, and MOTs-C.
Those were other experimental substances being considered. FDA staff opposed putting TB-500 on the final ingredient list [17][18]. The advisers' views can't grant your pharmacy permission; FDA decides.
As of September 2026, the advisers' votes remained unpublished by FDA.
So the July 2026 meeting doesn't give you a confirmed outcome. You can't treat a clinic's expectation as an agency decision.
Some clinics expected a change early in 2026.
They expected a change for roughly 14 peptides. Peptides are short chains of protein parts. Their expected change involved Category 2, which flags possible serious risks. They expected movement toward Category 1, which allows some temporary pharmacy use. Pharmacies must meet FDA's conditions while ingredients are reviewed.
Temporary use isn't permanent permission or drug approval.
Some clinic reports named specific 2026 dates for TB-500 leaving the risk group. Those same accounts described the move of TB-500 out of Category 2. Some acknowledged that a formal change of group was still pending.
FDA's cited notice didn't confirm those claimed change dates [18].
FDA.gov does confirm the Category 2 entry from 2023. On FDA's page current as of April 22, 2026, the request is withdrawn. FDA doesn't give a date for that change.
The page date can't tell you when the request changed.
A withdrawn request doesn't supply your pharmacy's permission.
Your pharmacy also needs permission to use the ingredient
What else does your prescription need? The pharmacy needs legal permission for the ingredient itself. Your doctor needs to check your health. Other licensed professionals who can prescribe may provide that review too.
The law covers two ways of making pharmacy medicines.
One covers a licensed pharmacist or doctor making medicine for you. The other covers larger batches made for clinics. FDA registers and inspects those larger facilities [17]. That registration doesn't allow every drug ingredient.
Neither law gives automatic permission to make TB-500 medicine.
You may meet your prescriber in person or by lawful video visit. The prescriber checks whether a pharmacy-made medicine fits your health. A prescription follows only when care and law allow.
Your video visit can't relax the ingredient rules.
Larger facilities can supply clinic medicines that meet those rules [17]. A larger facility doesn't automatically have permission for your ingredient. Your visit still needs a valid prescription and a proper review of your health [17].
Someone willing to prescribe can't supply missing ingredient permission.
For raw drug ingredients, the law allows several ways to qualify. An ingredient may be on FDA's permitted list. A substance already used in an approved drug can qualify too.
Published drug standards provide another way to qualify [17].
A drug-standards body publishes official descriptions of ingredients. The descriptions set tests for contents, strength, quality, and purity. An ingredient covered by those standards meets one legal condition. A pharmacy checking its own bottle isn't the same thing.
FDA now places TB-500 under withdrawn requests, outside the Category 2 group.
The safety warning remains beside the entry. FDA hasn't explained TB-500's pharmacy permission after withdrawal [16][17]. Finding a willing pharmacy doesn't answer that legal question for you.
Sport bans the substance under separate competition rules
Can a competitor use TB-500? Sport has a separate ban. The World Anti-Doping Agency makes competition drug rules. The separate ban covers TB-500 and thymosin beta-4 for growth and repair.
Tests detect those drugs in horse and human blood or urine.
Use in horse racing led to detection tests. Those tests find the chemical and what remains after breakdown. They don't tell you whether an injury healed.
A sport ban doesn't settle every other legal question.
These rules concern competitors and drug testing. Your own medical and legal circumstances need separate advice. This page doesn't offer a substance or decide your personal legal position.
TB-500's legal answer depends on the use involved
Your treatment doesn't have an approved TB-500 drug. FDA now lists a withdrawn request for pharmacy ingredient use. The safety warning remains beside that request.
FDA hasn't said how pharmacies may use the ingredient following withdrawal [16][17].
WADA, the agency setting sport's drug rules, also bans the substance. Your own legal circumstances need separate advice.
TB-500 pharmacy permission cannot come from a prescription alone
Your pharmacy needs an ingredient allowed under drug law [17]. FDA's permitted list is one way to qualify. Use in an approved drug is another. Official drug-standard books provide a third way.
FDA now puts the TB-500 request under withdrawn requests, outside Category 2, the warning group for possible serious risks [16][17].
The warning stayed, even though the request moved headings. FDA hasn't explained permission for pharmacy use after withdrawal. The July 2026 meeting discussed ingredient access. FDA hasn't released the advisers' votes [18].
Your prescription can't replace that unanswered ingredient question.
TB-500's request changed groups without gaining safety clearance
FDA originally listed TB-500, a thymosin beta-4 section, in Category 2. That group flags ingredients with possible serious risks. The September 29, 2023 update warned of missing safety knowledge and possible immune reactions [16].
Your immune system might attack the substance as something unwanted.
Some ingredients get temporary pharmacy permission under strict conditions. Category 2 ingredients don't get that allowance. FDA now lists the TB-500 request as withdrawn instead [17].
FDA hasn't said what pharmacy rules follow that withdrawal.
A changed heading doesn't mean the substance became safe for you.
TB-500 hasn't received approval as a treatment drug
FDA hasn't approved TB-500 for your treatment [16]. Calling a substance research material or animal research doesn't grant approval. The original FDA warning group, Category 2, flagged possible serious harm.
The pharmacy ingredient request is now listed as withdrawn [16][17].
That changes how the request is listed, rather than approving a drug. FDA hasn't explained whether pharmacies can make TB-500 medicines afterward.
You can't read withdrawal as either safety clearance or permission.
TB-500 is banned for competitors by WADA
WADA sets sport's drug rules and bans TB-500. The ban also covers thymosin beta-4 for growth and repair. Drug tests can find those substances and what remains after breakdown.
People and horses in competition face those restrictions.
Relevant bans also apply between events. You can't assume time away from competition removes the ban.
TB-500 horse use led scientists to develop drug tests
TB-500 drew attention as a lab-made substance used in horse sport. Scientists developed tests for horse blood and urine. The tests find the substance and what remains after breakdown.
That's why racehorses appear in accounts of the chemical.
You don't get healing evidence from a detection test. The sport ban also covers people. Horse use doesn't give your treatment permission.